Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

NCT02223052 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02223052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02223052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
October 27, 2014
Completion date
December 18, 2018
Enrollment
89 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, breast cancer, genitourinary, glioblastoma multiforme, hematological neoplasms, hodgkin's lymphoma, leukemia, lymphoma, melanoma, metastatic breast cancer, multiple myeloma, myelodysplastic syndromes, neoplasms, non-hodgkin's lymphoma, non-small cell lung cancer, osteosarcoma, renal cell carcinoma, sarcoma, small cell lung cancer, thyroid cancer